SELB
Price:
$0.8812
Market Cap:
$135.20M
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies c...[Read more]
Industry
Biotechnology
IPO Date
2016-06-22
Stock Exchange
NASDAQ
Ticker
SELB
According to Selecta Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 67.13%. This represents a change of -501.67% compared to the average of -16.71% of the last 4 quarters.
The mean historical ROE of Selecta Biosciences, Inc. over the last ten years is 77.38%. The current 67.13% ROE has changed -13.25% with respect to the historical average. Over the past ten years (40 quarters), SELB's ROE was at its highest in in the December 2018 quarter at 270.41%. The ROE was at its lowest in in the June 2019 quarter at -29275.00%.
Average
77.38%
Median
18.14%
Minimum
-637.56%
Maximum
1.21%
Discovering the peaks and valleys of Selecta Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 91.34%
Maximum Annual ROE = 1.21%
Minimum Annual Increase = -1056.55%
Minimum Annual ROE = -637.56%
Year | ROE | Change |
---|---|---|
2023 | 49.91% | 32.37% |
2022 | 37.71% | -133.06% |
2021 | -114.06% | -129.43% |
2020 | 387.58% | -160.79% |
2019 | -637.56% | -152.87% |
2018 | 1.21% | -1056.55% |
2017 | -126.07% | 91.34% |
2016 | -65.89% | -404.90% |
2015 | 21.61% | 47.23% |
The current ROE of Selecta Biosciences, Inc. (SELB) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-8.81%
5-year avg
-55.28%
10-year avg
77.38%
Selecta Biosciences, Inc.’s ROE is less than Paratek Pharmaceuticals, Inc. (22.36%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), greater than Immutep Limited (-42.11%), greater than Icosavax, Inc. (-41.24%), less than Checkpoint Therapeutics, Inc. (292.43%), less than Mustang Bio, Inc. (1.40%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Fortress Biotech, Inc. (-226.63%), greater than Kodiak Sciences Inc. (-77.23%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Eyenovia, Inc. (-615.55%), greater than Cognition Therapeutics, Inc. (-118.11%), greater than TransCode Therapeutics, Inc. (-597.47%), less than Gamida Cell Ltd. (187.96%), less than Rigel Pharmaceuticals, Inc. (46.64%), greater than Geron Corporation (-73.79%), greater than ImmunoGen, Inc. (-21.97%), greater than Cidara Therapeutics, Inc. (-401.89%), greater than Fortress Biotech, Inc. (-226.63%),
Company | ROE | Market cap |
---|---|---|
22.36% | $127.83M | |
-53.99% | $252.08M | |
-42.11% | $382.21M | |
-41.24% | $769.04M | |
292.43% | $93.07M | |
1.40% | $10.22M | |
7.96% | $44.68M | |
-226.63% | $44.00M | |
-77.23% | $121.54M | |
7.96% | $42.03M | |
-615.55% | $37.99M | |
-118.11% | $22.87M | |
-597.47% | $4.56M | |
187.96% | $4.34M | |
46.64% | $234.37M | |
-73.79% | $2.56B | |
-21.97% | $8.73B | |
-401.89% | $80.52M | |
-226.63% | $40.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Selecta Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Selecta Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Selecta Biosciences, Inc.'s ROE?
How is the ROE calculated for Selecta Biosciences, Inc. (SELB)?
What is the highest ROE for Selecta Biosciences, Inc. (SELB)?
What is the 3-year average ROE for Selecta Biosciences, Inc. (SELB)?
What is the 5-year average ROE for Selecta Biosciences, Inc. (SELB)?
How does the current ROE for Selecta Biosciences, Inc. (SELB) compare to its historical average?